Project Grant R15EB040033
- The National Institute of Biomedical Imaging and Bioengineering awarded Wake Forest University Health Sciences $228,195 on July 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate multimodal predictive models for radiation failure patterns and survival outcomes in patients with brain metastases from non-small cell lung cancer. The research integrates pre-treatment magnetic resonance imaging, blood...
- The National Institute of Biomedical Imaging and Bioengineering awarded Duke University $1,523,343 on March 10, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop four-dimensional smart epidermal photoacoustic tomography (4D-SEPAT) technology for real-time, longitudinal functional brain imaging in behaving non-human primates. The 4D-SEPAT system integrates soft ultrasound transducer arrays with integrated shape...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of North Carolina at Chapel Hill $610,678 on July 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop two innovative short echo-time magnetic resonance imaging technologies for advanced functional MRI applications. The recipient will develop, optimize, and benchmark SORDINO (steady-state on-the-ramp detection of...
- Wake Forest University Health Sciences received a $13.43 million Cooperative Agreement from the Advanced Research Projects Agency for Health (ARPA-H, CFDA 93.384) awarded September 26, 2025, with completion targeted for September 25, 2028. The award funds development of bioprinted vascularized autologous renal tissue constructs designed to augment renal function in patients with kidney disease. The institute will leverage its two decades of experience in three-dimensional (3D) printing...
- The Defense Health Agency awarded Wake Forest University Health Sciences $1.143 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) for validation of in vitro and in vivo paired models of jet fuel exposures for biomarker identification. Work is performed in Winston-Salem, North Carolina, with a period of performance extending through June 30, 2029. The project validates paired laboratory and animal models to identify biomarkers associated with jet...
- The Defense Health Agency awarded Wake Forest University Health Sciences $1,799,493 on October 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to develop PEDF-enriched exosomes for improving urethral sphincter function after radical prostatectomy. The award funds research through September 30, 2028, and is performed in Winston-Salem, North Carolina. Wake Forest University Health Sciences leads the project with University of California, Davis as a sub-recipient....
- The National Science Foundation Division of Electrical, Communications and Cyber Systems awarded Wake Forest University $306,341 on October 15, 2026, for collaborative research under the Engineering program (CFDA 47.041) to develop a predictive device physics framework for high-performance organic electrochemical transistors. The project, conducted in collaboration with Princeton University, will establish fundamental understanding of how organic electrochemical transistors operate and create...
- The National Institute of Biomedical Imaging and Bioengineering awarded Duke University $586,406 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) on May 1, 2026. The award funds research on immunomodulatory self-assembled peptides (ISAP), a supramolecular biomaterial technology designed to engage natural autoantibodies and modulate immune responses for treatment of chronic inflammatory diseases. The research addresses...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Tennessee, operating as the Space Institute, $157,000 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The recipient will develop novel structured glass-ceramic scintillator conversion screens to improve image quality and reduce dose in X-ray imaging applications using indirect flat panel detectors at megavoltage...
- The National Institutes of Health Office of the Director awarded $395,860 to The Regents of the University of California, operating Lawrence Berkeley National Laboratory, on September 16, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to develop a non-invasive biodosimeter for radiological emergency triage. The recipient will use Fourier Transform Infrared Attenuated Total Reflection (FTIR-ATR) imaging coupled with statistical machine learning models to distinguish irradiated...
The National Institute of Biomedical Imaging and Bioengineering awarded Wake Forest University $425,663 on August 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop skin-conformal, tissue-equivalent wearable dosimeter platforms for radiotherapy precision. The project, titled "Enhancing Radiotherapy Precision with Conformal, Tissue-Equivalent Dosimeters," addresses limitations in current clinical dosimetry—insufficient accuracy, lack of real-time monitoring, and poor spatial resolution in complex treatment scenarios. Wake Forest will design, fabricate, and validate a flexible radiation-sensitive organic field-effect transistor (RAD-OFET) platform that uses organic semiconductors with radiation absorption properties mimicking human tissue, eliminating the need for dose-correction factors. The inherent mechanical compliance of these devices enables direct, conformal application to skin for high-fidelity in vivo dose mapping, allowing clinicians to optimize treatment plans in real time and improve patient outcomes. The research comprises three specific aims: engineering RAD-OFET architectures with monotonic, sensitive dosimetric response; scaling single-pixel devices into uniform, large-area flexible RAD-OFET arrays; and validating dosimetric performance in clinically mimicked settings. The project is supported by strong preliminary results, including a relevant U.S. patent. Performance occurs in Winston-Salem, North Carolina. The period of performance runs from August 1, 2026, through July 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $425.7k | 7/21/26 |